Skip to main content
Top
Published in: Osteoporosis International 12/2013

01-12-2013 | Original Article

Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women

Authors: S. H. Ahn, S. H. Lee, B.-J. Kim, K.-H. Lim, S. J. Bae, E. H. Kim, H.-K. Kim, J. W. Choe, J.-M. Koh, G. S. Kim

Published in: Osteoporosis International | Issue 12/2013

Login to get access

Abstract

Summary

Higher serum uric acid (UA) was associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in postmenopausal women. Furthermore, UA suppressed osteoclastogenesis and decreased production of reactive oxygen species in osteoclast precursors, indicating UA may have beneficial effects on bone metabolism as an antioxidant.

Introduction

UA is known to play a physiological role as an antioxidant, and oxidative stress has detrimental effects on bone metabolism. In the present study, we investigated the association of serum UA level with the osteoporosis-related phenotypes and its direct effect on bone-resorbing osteoclasts using in vitro systems.

Methods

This is a large cross-sectional study, including 7,502 healthy postmenopausal women. Bone mineral density (BMD) and serum UA concentrations were obtained from all subjects. Data on bone turnover markers and lateral thoracolumbar radiographs were available for 1,023 and 6,918 subjects, respectively. An in vitro study investigated osteoclastogenesis and reactive oxygen species (ROS) levels according to UA treatment.

Results

After adjusting for multiple confounders, serum UA levels were positively associated with BMD at all sites (all p < 0.001). Compared with the participants in the highest UA quartile, the odds for osteoporosis were 40 % higher in those in the lowest quartile. The serum UA levels were inversely related to both serum C-terminal telopeptide of type I collagen and osteocalcin levels (p < 0.001 and p = 0.004, respectively). Consistently, subjects with vertebral fracture had lower serum UA levels, compared with those without it (p = 0.009). An in vitro study showed that UA decreased osteoclastogenesis in a dose-dependent manner and reduced the production of ROS in osteoclast precursors.

Conclusion

These results provide epidemiological and experimental evidence that serum UA may have a beneficial effect on bone metabolism as an antioxidant in postmenopausal women.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, Yang XF (2012) Uric acid, hyperuricemia and vascular diseases. Front Biosci 17:656–669CrossRef Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, Yang XF (2012) Uric acid, hyperuricemia and vascular diseases. Front Biosci 17:656–669CrossRef
2.
go back to reference Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G (2009) Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 266:558–570PubMedCrossRef Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G (2009) Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 266:558–570PubMedCrossRef
3.
go back to reference Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811–1821PubMedCrossRef Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811–1821PubMedCrossRef
4.
go back to reference Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442–447PubMedCrossRef Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442–447PubMedCrossRef
5.
6.
go back to reference Sautin YY, Johnson RJ (2008) Uric acid: the oxidant–antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 27:608–619PubMedCrossRef Sautin YY, Johnson RJ (2008) Uric acid: the oxidant–antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 27:608–619PubMedCrossRef
7.
go back to reference Berry CE, Hare JM (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555:589–606PubMedCrossRef Berry CE, Hare JM (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555:589–606PubMedCrossRef
8.
go back to reference Duan X, Ling F (2008) Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? Med Hypotheses 70:578–581PubMedCrossRef Duan X, Ling F (2008) Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? Med Hypotheses 70:578–581PubMedCrossRef
9.
go back to reference Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106:3073–3078PubMedCrossRef Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106:3073–3078PubMedCrossRef
10.
go back to reference Chambers DE, Parks DA, Patterson G, Roy R, Mccord JM, Yoshida S, Parmley LF, Downey JM (1985) Xanthine-oxidase as a source of free-radical damage in myocardial ischemia. J Mol Cell Cardiol 17:145–152PubMedCrossRef Chambers DE, Parks DA, Patterson G, Roy R, Mccord JM, Yoshida S, Parmley LF, Downey JM (1985) Xanthine-oxidase as a source of free-radical damage in myocardial ischemia. J Mol Cell Cardiol 17:145–152PubMedCrossRef
11.
go back to reference Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105:2619–2624PubMedCrossRef Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105:2619–2624PubMedCrossRef
12.
go back to reference Waring WS, Webb DJ, Maxwell SRJ (2001) Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharm 38:365–371CrossRef Waring WS, Webb DJ, Maxwell SRJ (2001) Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharm 38:365–371CrossRef
13.
go back to reference Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF (2010) Uric acid as a CNS antioxidant. J Alzheimers Dis 19:1331–1336PubMed Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF (2010) Uric acid as a CNS antioxidant. J Alzheimers Dis 19:1331–1336PubMed
14.
go back to reference Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, Wills AM (2012) Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 259:1923–1928PubMedCrossRef Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, Wills AM (2012) Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 259:1923–1928PubMedCrossRef
15.
go back to reference Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR (1990) Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 85:632–639PubMedCrossRef Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR (1990) Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 85:632–639PubMedCrossRef
16.
go back to reference Ha H, Kwak HB, Lee SW, Jin HM, Kim HM, Kim HH, Lee ZH (2004) Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 301:119–127PubMedCrossRef Ha H, Kwak HB, Lee SW, Jin HM, Kim HM, Kim HH, Lee ZH (2004) Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 301:119–127PubMedCrossRef
17.
go back to reference Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ (2004) Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappa B. Biochem Bioph Res Co 314:197–207CrossRef Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ (2004) Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappa B. Biochem Bioph Res Co 314:197–207CrossRef
18.
go back to reference Park BG, Yoo CI, Kim HT, Kwon CH, Kim YK (2005) Role of mitogen-activated protein kinases in hydrogen peroxide-induced cell death in osteoblastic cells. Toxicology 215:115–125PubMedCrossRef Park BG, Yoo CI, Kim HT, Kwon CH, Kim YK (2005) Role of mitogen-activated protein kinases in hydrogen peroxide-induced cell death in osteoblastic cells. Toxicology 215:115–125PubMedCrossRef
19.
go back to reference Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, Senin U, Pacifici R, Cherubini A (2003) Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 88:1523–1527PubMedCrossRef Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, Senin U, Pacifici R, Cherubini A (2003) Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 88:1523–1527PubMedCrossRef
20.
go back to reference Sánchez-Rodríguez M, Ruiz-Ramos M, Correa-Muñoz E, Mendoza-Núñez V (2007) Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet Disord 8:124PubMedCrossRef Sánchez-Rodríguez M, Ruiz-Ramos M, Correa-Muñoz E, Mendoza-Núñez V (2007) Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet Disord 8:124PubMedCrossRef
21.
go back to reference Sontakke AN, Tare RS (2002) A duality in the roles of reactive oxygen species with respect to bone metabolism. Clin Chim Acta 318:145–148PubMedCrossRef Sontakke AN, Tare RS (2002) A duality in the roles of reactive oxygen species with respect to bone metabolism. Clin Chim Acta 318:145–148PubMedCrossRef
22.
go back to reference Hall SL, Greendale GA (1998) The relation of dietary vitamin C intake to bone mineral density: results from the PEPI study. Calcif Tissue Int 63:183–189PubMedCrossRef Hall SL, Greendale GA (1998) The relation of dietary vitamin C intake to bone mineral density: results from the PEPI study. Calcif Tissue Int 63:183–189PubMedCrossRef
23.
go back to reference Melhus H, Michaelsson K, Holmberg L, Wolk A, Ljunghall S (1999) Smoking, antioxidant vitamins, and the risk of hip fracture. J Bone Miner Res 14:129–135PubMedCrossRef Melhus H, Michaelsson K, Holmberg L, Wolk A, Ljunghall S (1999) Smoking, antioxidant vitamins, and the risk of hip fracture. J Bone Miner Res 14:129–135PubMedCrossRef
24.
go back to reference Rao L, Mackinnon E, Josse R, Murray T, Strauss A, Rao A (2007) Lycopene consumption decreases oxidative stress and bone resorption markers in postmenopausal women. Osteoporosis Int 18:109–115CrossRef Rao L, Mackinnon E, Josse R, Murray T, Strauss A, Rao A (2007) Lycopene consumption decreases oxidative stress and bone resorption markers in postmenopausal women. Osteoporosis Int 18:109–115CrossRef
25.
go back to reference Mackinnon E, Rao A, Josse R, Rao L (2011) Supplementation with the antioxidant lycopene significantly decreases oxidative stress parameters and the bone resorption marker N-telopeptide of type I collagen in postmenopausal women. Osteoporosis Int 22:1091–1101CrossRef Mackinnon E, Rao A, Josse R, Rao L (2011) Supplementation with the antioxidant lycopene significantly decreases oxidative stress parameters and the bone resorption marker N-telopeptide of type I collagen in postmenopausal women. Osteoporosis Int 22:1091–1101CrossRef
26.
go back to reference Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, Urry ZL, Chambers TJ (2003) A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 112:915–923PubMed Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, Urry ZL, Chambers TJ (2003) A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 112:915–923PubMed
27.
go back to reference Donghui MM (2010) Moderate levels of plasma uric acid could promote fracture healing. Med Hypotheses 75:682PubMedCrossRef Donghui MM (2010) Moderate levels of plasma uric acid could promote fracture healing. Med Hypotheses 75:682PubMedCrossRef
28.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
29.
go back to reference Kiel D (1995) Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures. J Bone Miner Res 10:518–523PubMed Kiel D (1995) Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures. J Bone Miner Res 10:518–523PubMed
30.
go back to reference Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148PubMedCrossRef Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148PubMedCrossRef
31.
go back to reference Yoneda M, Takatsuki K, Tomita A (1983) Parathyroid function and uric acid metabolism. Nihon Naibunpi Gakkai Zasshi 59:1738–1751PubMed Yoneda M, Takatsuki K, Tomita A (1983) Parathyroid function and uric acid metabolism. Nihon Naibunpi Gakkai Zasshi 59:1738–1751PubMed
32.
go back to reference Hui JY, Choi JW, Mount DB, Zhu Y, Zhang Y, Choi HK (2012) The independent association between parathyroid hormone levels and hyperuricemia: a national population study. Arthritis Res Ther 14:R56. doi:10.1186/ar3769 PubMedCrossRef Hui JY, Choi JW, Mount DB, Zhu Y, Zhang Y, Choi HK (2012) The independent association between parathyroid hormone levels and hyperuricemia: a national population study. Arthritis Res Ther 14:R56. doi:10.​1186/​ar3769 PubMedCrossRef
33.
go back to reference Miller PD (2008) Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 6:12–16PubMedCrossRef Miller PD (2008) Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 6:12–16PubMedCrossRef
34.
go back to reference Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Yamakita J, Higashino K (1998) Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. Metabolism 47:336–338PubMedCrossRef Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Yamakita J, Higashino K (1998) Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. Metabolism 47:336–338PubMedCrossRef
35.
go back to reference Vanholder R, Patel S, Hsu CH (1993) Effect of uric acid on plasma levels of 1,25(OH)2D in renal failure. J Am Soc Nephrol 4:1035–1038PubMed Vanholder R, Patel S, Hsu CH (1993) Effect of uric acid on plasma levels of 1,25(OH)2D in renal failure. J Am Soc Nephrol 4:1035–1038PubMed
36.
go back to reference Nabipour I, Sambrook PN, Blyth FM, Janu MR, Waite LM, Naganathan V, Handelsman DJ, Le Couteur DG, Cumming RG, Seibel MJ (2011) Serum uric acid is associated with bone health in older men: a cross–sectional population–based study. J Bone Miner Res 26:955–964PubMedCrossRef Nabipour I, Sambrook PN, Blyth FM, Janu MR, Waite LM, Naganathan V, Handelsman DJ, Le Couteur DG, Cumming RG, Seibel MJ (2011) Serum uric acid is associated with bone health in older men: a cross–sectional population–based study. J Bone Miner Res 26:955–964PubMedCrossRef
37.
go back to reference Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ (2005) Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 146:728–735PubMedCrossRef Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ (2005) Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 146:728–735PubMedCrossRef
38.
go back to reference Hamidi MS, Corey PN, Cheung AM (2012) Effects of vitamin E on bone turnover markers among US postmenopausal women. J Bone Miner Res 27:1368–1380PubMedCrossRef Hamidi MS, Corey PN, Cheung AM (2012) Effects of vitamin E on bone turnover markers among US postmenopausal women. J Bone Miner Res 27:1368–1380PubMedCrossRef
39.
go back to reference Leveille SG, LaCroix AZ, Koepsell TD, Beresford SA, Van Belle G, Buchner DM (1997) Dietary vitamin C and bone mineral density in postmenopausal women in Washington State, USA. J Epidemiol Community Health 51:479–485PubMedCrossRef Leveille SG, LaCroix AZ, Koepsell TD, Beresford SA, Van Belle G, Buchner DM (1997) Dietary vitamin C and bone mineral density in postmenopausal women in Washington State, USA. J Epidemiol Community Health 51:479–485PubMedCrossRef
40.
go back to reference Jagger CJ, Lean JM, Davies JT, Chambers TJ (2005) Tumor necrosis factor-alpha mediates osteopenia caused by depletion of antioxidants. Endocrinology 146:113–118PubMedCrossRef Jagger CJ, Lean JM, Davies JT, Chambers TJ (2005) Tumor necrosis factor-alpha mediates osteopenia caused by depletion of antioxidants. Endocrinology 146:113–118PubMedCrossRef
42.
go back to reference Makovey J, Macara M, Chen JS, Hayward CS, March L, Seibel MJ, Sambrook PN (2013) Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: a longitudinal study. Bone 52:400–406PubMedCrossRef Makovey J, Macara M, Chen JS, Hayward CS, March L, Seibel MJ, Sambrook PN (2013) Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: a longitudinal study. Bone 52:400–406PubMedCrossRef
43.
go back to reference Brown JP, Albert C, Nassar BA et al (2009) Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 42:929–942PubMedCrossRef Brown JP, Albert C, Nassar BA et al (2009) Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 42:929–942PubMedCrossRef
44.
go back to reference Shin CS, Kim MJ, Shim SM et al (2012) The prevalence and risk factors of vertebral fractures in Korea. J Bone Miner Metab 30:183–192PubMedCrossRef Shin CS, Kim MJ, Shim SM et al (2012) The prevalence and risk factors of vertebral fractures in Korea. J Bone Miner Metab 30:183–192PubMedCrossRef
Metadata
Title
Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women
Authors
S. H. Ahn
S. H. Lee
B.-J. Kim
K.-H. Lim
S. J. Bae
E. H. Kim
H.-K. Kim
J. W. Choe
J.-M. Koh
G. S. Kim
Publication date
01-12-2013
Publisher
Springer London
Published in
Osteoporosis International / Issue 12/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2377-7

Other articles of this Issue 12/2013

Osteoporosis International 12/2013 Go to the issue